These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30686091)

  • 1. Interleukin-6 in juvenile idiopathic arthritis.
    Akioka S
    Mod Rheumatol; 2019 Mar; 29(2):275-286. PubMed ID: 30686091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tocilizumab for treating juvenile idiopathic arthritis.
    Turnier JL; Brunner HI
    Expert Opin Biol Ther; 2016; 16(4):559-66. PubMed ID: 26848760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab for the treatment of systemic juvenile idiopathic arthritis.
    Herlin T
    Expert Rev Clin Immunol; 2012 Aug; 8(6):517-25. PubMed ID: 22992145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
    Shepherd J; Cooper K; Harris P; Picot J; Rose M
    Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leucine-rich α2-glycoprotein as the acute-phase reactant to detect systemic juvenile idiopathic arthritis disease activity during anti-interleukin-6 blockade therapy: A case series.
    Shimizu M; Nakagishi Y; Inoue N; Mizuta M; Yachie A
    Mod Rheumatol; 2017 Sep; 27(5):833-837. PubMed ID: 28094589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-6 blockers in systemic onset juvenile idiopathic arthritis.
    Barone P; Pignataro R; Garozzo MT; Leonardi S
    Immunotherapy; 2016; 8(1):79-87. PubMed ID: 26642378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement.
    Schoels MM; van der Heijde D; Breedveld FC; Burmester GR; Dougados M; Emery P; Ferraccioli G; Gabay C; Gibofsky A; Gomez-Reino JJ; Jones G; Kvien TK; Murakami M; Nishimoto N; Smolen JS
    Ann Rheum Dis; 2013 Apr; 72(4):583-9. PubMed ID: 23144446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proinflammatory Cytokine Environments Can Drive Interleukin-17 Overexpression by γ/δ T Cells in Systemic Juvenile Idiopathic Arthritis.
    Kessel C; Lippitz K; Weinhage T; Hinze C; Wittkowski H; Holzinger D; Fall N; Grom AA; Gruen N; Foell D
    Arthritis Rheumatol; 2017 Jul; 69(7):1480-1494. PubMed ID: 28296284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Interleukin-6 as a pathogenic factor of systemic-onset juvenile idiopathic arthritis].
    Yokota S
    Nihon Rinsho Meneki Gakkai Kaishi; 2008 Apr; 31(2):99-103. PubMed ID: 18446012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tocilizumab treatment in juvenile idiopathic arthritis patients: A single center experience.
    Demir S; Sönmez HE; Arslanoğlu-Aydın E; Özen S; Bilginer Y
    Turk J Pediatr; 2019; 61(2):180-185. PubMed ID: 31951328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analysis.
    Doeleman MJH; van Maarseveen EM; Swart JF
    Rheumatology (Oxford); 2019 Oct; 58(10):1839-1849. PubMed ID: 30809664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of disease activity and tumour necrosis factor-α inhibitor therapy on cytokine levels in juvenile idiopathic arthritis.
    Walters HM; Pan N; Lehman TJ; Adams A; Kalliolias GD; Zhu YS; Santiago F; Nguyen J; Sitaras L; Cunningham-Rundles S; Walsh TJ; Toussi SS
    Clin Exp Immunol; 2016 Jun; 184(3):308-17. PubMed ID: 26934060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab in pediatric rheumatology: the clinical experience.
    Gurion R; Singer NG
    Curr Rheumatol Rep; 2013 Jul; 15(7):338. PubMed ID: 23715975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics of influenza virus infection in juvenile idiopathic arthritis patients treated with tocilizumab.
    Kawada J; Kitagawa Y; Iwata N; Ito Y
    Mod Rheumatol; 2013 Sep; 23(5):972-6. PubMed ID: 23070362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Summary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis.
    McMahan R; Balfe LM; Greene L
    J Manag Care Pharm; 2012; 18(1 Suppl B):1-16. PubMed ID: 22376227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
    Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
    Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic Juvenile Idiopathic Arthritis: Diagnosis and Management.
    Kumar S
    Indian J Pediatr; 2016 Apr; 83(4):322-7. PubMed ID: 26916892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of juvenile idiopathic arthritis in the biologic age.
    Stoll ML; Cron RQ
    Rheum Dis Clin North Am; 2013 Nov; 39(4):751-66. PubMed ID: 24182853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis.
    Kostik MM; Dubko MF; Masalova VV; Snegireva LS; Kornishina TL; Chikova IA; Isupova EA; Kuchinskaya EM; Glebova NI; Buchinskaya NV; Kalashnikova OV; Chasnyk VG
    Pediatr Rheumatol Online J; 2015; 13():4. PubMed ID: 25685108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic juvenile idiopathic arthritis: New insights into pathogenesis and cytokine directed therapies.
    Pardeo M; Bracaglia C; De Benedetti F
    Best Pract Res Clin Rheumatol; 2017 Aug; 31(4):505-516. PubMed ID: 29773270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.